Understanding gout and uncontrolled gout:

OVERVIEW OF THE DISEASE STATE, CLINICAL BURDEN, AND TREATMENT LANDSCAPE

Episode 6: What does the treatment landscape for uncontrolled gout look like?

Brian LaMoreaux, MD, MS, discusses the treatment landscape for uncontrolled gout, including data on treatment usage and managing patients’ serum uric acid levels.

Episode 1

What do gout and uncontrolled gout look like?

Episode 2

How does gout progress?

Episode 3

What is the role of urate deposition in gout disease progression?

Episode 4

What are the short- and long-term effects of uncontrolled gout, especially...

Episode 5

What are some recommended treatment approaches for chronic gout?

Episode 6

What does the treatment landscape for uncontrolled gout look like?

Episode 7

What are some medication considerations for patients with uncontrolled gou...

Episode 8

Frequently asked questions about gout and uncontrolled gout

Clinical Perspectives Presented by:

Brian LaMoreaux, MD, MS

Internist and Rheumatologist

Executive Medical Director, Amgen

Chris Doan, MBA, PA-Certified

Senior Director,

Access Strategy, RDBU, Amgen

Program Objectives

In this series, Dr. Brian LaMoreaux explains how to:

Understand the underlying disease and recognize signs of progression in chronic gout and uncontrolled gout

Recognize elements of the clinical burden of chronic gout and the importance of lowering serum uric acid to reduce this burden

Identify urate-lowering therapies and their place in the U.S. gout treatment landscape

Please note that Amgen acquired Horizon Therapeutics on October 6, 2023.

©2024 Horizon Therapeutics USA, Inc.

DA-UNBR-US-02393 02/24